Sugi Predict

Sugi Predict / Targets / CDC42BPB

CDC42BPB

Serine/threonine-protein kinase MRCK beta · Q9Y5S2 · CDC42BPB on Sugi Atlas →

12,243 patent compounds predicted against CDC42BPB, 4,936 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1836793 SCHEMBL1836793 0.71 20/20
SCHEMBL1840475 SCHEMBL1840475 0.69 20/20
SCHEMBL1839465 SCHEMBL1839465 0.66 20/20
SCHEMBL2244751 SCHEMBL2244751 0.65 20/20
SCHEMBL2238960 SCHEMBL2238960 0.61 20/20
SCHEMBL2242056 SCHEMBL2242056 0.79 19/20
SCHEMBL1839716 SCHEMBL1839716 0.75 19/20
SCHEMBL1842497 SCHEMBL1842497 0.75 19/20
SCHEMBL1837797 SCHEMBL1837797 0.67 19/20
SCHEMBL1837829 SCHEMBL1837829 0.67 19/20
SCHEMBL1842183 SCHEMBL1842183 0.67 19/20
SCHEMBL1838095 SCHEMBL1838095 0.64 19/20
SCHEMBL1840586 SCHEMBL1840586 0.62 19/20
SCHEMBL2241048 SCHEMBL2241048 0.56 19/20
SCHEMBL1837484 SCHEMBL1837484 0.54 19/20
SCHEMBL2236999 SCHEMBL2236999 0.73 18/20
SCHEMBL1838633 SCHEMBL1838633 0.66 18/20
SCHEMBL1839180 SCHEMBL1839180 0.68 17/20
SCHEMBL1836357 SCHEMBL1836357 0.67 17/20
SCHEMBL1841846 SCHEMBL1841846 0.66 17/20

Clinical trials — most relevant to CDC42BPB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Cetuximab in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Role of Chemokine and Chemokine Receptor in Psoriasis nanWITHDRAWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC42BPB binder may also engage these)

ProteinNameSimilarity
Q7TT50 — 1.000 Q7TT50 →
CDC42BPA Serine/threonine-protein kinase MRCK alpha 1.000 landscape →
O54874 — 1.000 O54874 →
Q7TT49 — 1.000 Q7TT49 →
Q62868 — 0.997 Q62868 →
Q3UU96 — 0.997 Q3UU96 →
Q28021 — 0.996 Q28021 →
P70336 — 0.996 P70336 →
M3TYT0 — 0.994 M3TYT0 →
A7MD70 — 0.994 A7MD70 →
F1NBT0 — 0.993 F1NBT0 →
Q08DR9 — 0.993 Q08DR9 →
A5WW21 — 0.993 A5WW21 →
A8WVU9 — 0.993 A8WVU9 →
Q6NRW2 — 0.993 Q6NRW2 →
Q6NRC9 — 0.993 Q6NRC9 →
Q6ZU80 — 0.993 Q6ZU80 →
Q7YS99 — 0.993 Q7YS99 →
Q5ZKK5 — 0.992 Q5ZKK5 →
Q5BJF6 — 0.992 Q5BJF6 →
Q8TDM6 — 0.992 Q8TDM6 →
Q5BIX7 — 0.991 Q5BIX7 →
Q22908 — 0.991 Q22908 →
P92199 — 0.991 P92199 →
Q9W1B0 — 0.991 Q9W1B0 →
Q6NZW0 — 0.991 Q6NZW0 →
Q9H1H9 — 0.991 Q9H1H9 →
P28738 — 0.991 P28738 →
P70335 — 0.991 P70335 →
ROCK2 Rho-associated protein kinase 2 0.991 landscape →